ADAR RNA editing in human disease; more to it than meets the I
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu časopisecké články, přehledy
Grantová podpora
621368
EU - International
17615
AIRC IG - International
PubMed
28913566
DOI
10.1007/s00439-017-1837-0
PII: 10.1007/s00439-017-1837-0
Knihovny.cz E-zdroje
- MeSH
- adenosindeaminasa * genetika metabolismus MeSH
- duševní poruchy * genetika metabolismus MeSH
- dvouvláknová RNA * genetika metabolismus MeSH
- editace RNA genetika MeSH
- lidé MeSH
- mutace * MeSH
- mutantní kmeny myší MeSH
- myši MeSH
- nemoci nervového systému * genetika metabolismus MeSH
- proteiny vázající RNA * genetika metabolismus MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- ADAR protein, human MeSH Prohlížeč
- ADAR1 protein, mouse MeSH Prohlížeč
- ADAR2 protein, mouse MeSH Prohlížeč
- ADARB1 protein, human MeSH Prohlížeč
- adenosindeaminasa * MeSH
- dvouvláknová RNA * MeSH
- proteiny vázající RNA * MeSH
We review the structures and functions of ADARs and their involvements in human diseases. ADAR1 is widely expressed, particularly in the myeloid component of the blood system, and plays a prominent role in promiscuous editing of long dsRNA. Missense mutations that change ADAR1 residues and reduce RNA editing activity cause Aicardi-Goutières Syndrome, a childhood encephalitis and interferonopathy that mimics viral infection and resembles an extreme form of Systemic Lupus Erythmatosus (SLE). In Adar1 mouse mutant models aberrant interferon expression is prevented by eliminating interferon activation signaling from cytoplasmic dsRNA sensors, indicating that unedited cytoplasmic dsRNA drives the immune induction. On the other hand, upregulation of ADAR1 with widespread promiscuous RNA editing is a prominent feature of many cancers and particular site-specific RNA editing events are also affected. ADAR2 is most highly expressed in brain and is primarily required for site-specific editing of CNS transcripts; recent findings indicate that ADAR2 editing is regulated by neuronal excitation for synaptic scaling of glutamate receptors. ADAR2 is also linked to the circadian clock and to sleep. Mutations in ADAR2 could contribute to excitability syndromes such as epilepsy, to seizures, to diseases involving neuronal plasticity defects, such as autism and Fragile-X Syndrome, to neurodegenerations such as ALS, or to astrocytomas or glioblastomas in which reduced ADAR2 activity is required for oncogenic cell behavior. The range of human disease associated with ADAR1 mutations may extend further to include other inflammatory conditions while ADAR2 mutations may affect psychiatric conditions.
CEITEC Masaryk University Kamenice 753 5 Pavilion A35 Brno 62 500 Czech Republic
Oncohaematology Department Ospedale Pediatrico Bambino Gesù Viale di San Paolo 15 00146 Rome Italy
Zobrazit více v PubMed
EMBO J. 1995 Jul 17;14(14):3563-71 PubMed
Neuroscience. 2000;95(3):869-79 PubMed
Nat Cell Biol. 2015 Mar;17(3):311-21 PubMed
J Biol Chem. 2008 Mar 14;283(11):7251-60 PubMed
Nat Commun. 2016 Jan 27;7:10512 PubMed
Cell Rep. 2014 Nov 20;9(4):1482-94 PubMed
J Biol Chem. 2006 Nov 3;281(44):33386-94 PubMed
Nature. 2000 Jul 6;406(6791):78-81 PubMed
Science. 1999 Jun 11;284(5421):1841-5 PubMed
Nat Commun. 2011;2:319 PubMed
Nature. 2011 Mar 24;471(7339):473-9 PubMed
Nucleic Acids Res. 2017 Apr 7;45(6):3369-3377 PubMed
Cell. 1988 Dec 23;55(6):1089-98 PubMed
Biochemistry. 2000 Oct 24;39(42):12875-84 PubMed
Front Neurosci. 2013 Apr 18;7:61 PubMed
Nat Med. 2013 Feb;19(2):209-16 PubMed
Genome Res. 2011 Sep;21(9):1506-11 PubMed
J Med Genet. 2014 Feb;51(2):76-82 PubMed
Curr Opin Neurobiol. 2007 Jun;17(3):289-97 PubMed
Bioinformatics. 2016 Jul 15;32(14 ):2213-5 PubMed
Neuron. 2013 Oct 16;80(2):415-28 PubMed
Genome Res. 2012 Jul;22(7):1266-81 PubMed
RNA. 2000 May;6(5):755-67 PubMed
EMBO J. 1998 Dec 15;17(24):7505-13 PubMed
Nucleic Acids Res. 2007;35(11):3723-32 PubMed
Science. 1994 Dec 9;266(5191):1709-13 PubMed
Neurobiol Dis. 2012 Mar;45(3):1121-8 PubMed
Immunity. 2011 Jun 24;34(6):866-78 PubMed
Neuroscience. 2011 Aug 25;189:305-15 PubMed
Mol Biol Cell. 2002 Nov;13(11):3822-35 PubMed
Genome Biol. 2015 Jan 13;16:5 PubMed
PLoS One. 2012;7(3):e33720 PubMed
J Cell Sci. 2017 Feb 15;130(4):745-753 PubMed
Neuropharmacology. 2009 Jan;56(1):2-5 PubMed
Int J Cancer. 2013 Apr 15;132(8):1741-50 PubMed
J Biol Chem. 2017 Mar 10;292(10 ):4326-4335 PubMed
Genome Res. 2014 Mar;24(3):365-76 PubMed
RNA Biol. 2017 Feb;14 (2):164-170 PubMed
Hum Genet. 1997 Sep;100(3-4):398-400 PubMed
J Biol Chem. 2007 Aug 3;282(31):22448-59 PubMed
Cell Rep. 2015 Oct 13;13(2):277-89 PubMed
Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12465-70 PubMed
J Biol Chem. 2004 Feb 6;279(6):4952-61 PubMed
Nucleic Acids Res. 2013 Nov;41(21):9786-99 PubMed
Curr Top Microbiol Immunol. 2012;353:197-220 PubMed
Cancer Cell. 2015 Oct 12;28(4):515-528 PubMed
Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10979-83 PubMed
PLoS One. 2011;6(9):e25350 PubMed
Mol Psychiatry. 2008 Nov;13(11):1001-10 PubMed
Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14687-92 PubMed
Exp Neurol. 2016 Jan;275 Pt 1:162-71 PubMed
J Hum Genet. 2015 Nov;60(11):657-64 PubMed
J Biol Chem. 1999 Apr 2;274(14):9472-8 PubMed
Nat Genet. 2012 Nov;44(11):1243-8 PubMed
J Clin Invest. 2013 Jun;123(6):2703-18 PubMed
Genome Biol. 2017 Jul 28;18(1):143 PubMed
Cell. 2010 Mar 19;140(6):771-6 PubMed
Immunology. 2003 May;109(1):15-23 PubMed
Science. 2015 Sep 4;349(6252):1115-20 PubMed
Nat Biotechnol. 2012 Feb 12;30(3):253-60 PubMed
Nat Immunol. 2009 Jan;10(1):109-15 PubMed
Cell. 1987 Feb 27;48(4):599-605 PubMed
PLoS Biol. 2004 Dec;2(12):e391 PubMed
Nat Commun. 2015 Mar 09;6:6355 PubMed
Oncogene. 2013 Feb 21;32(8):998-1009 PubMed
Cell Rep. 2013 Nov 14;5(3):849-60 PubMed
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14018-23 PubMed
Gene. 2000 May 30;250(1-2):53-60 PubMed
EMBO J. 2009 Oct 21;28(20):3145-56 PubMed
Nature. 1997 May 15;387(6630):303-8 PubMed
Nature. 2009 Oct 8;461(7265):809-13 PubMed
Mol Brain. 2014 Jan 21;7:5 PubMed
RNA Biol. 2017 Jun 22;:1-12 PubMed
Cell. 1987 Feb 27;48(4):607-13 PubMed
J Biol Chem. 2004 Feb 6;279(6):4894-902 PubMed
Bioessays. 2008 Nov;30(11-12):1185-92 PubMed
Nat Genet. 2017 Jan;49(1):146-151 PubMed
EMBO J. 2000 Mar 1;19(5):997-1009 PubMed
J Exp Med. 2014 Apr 7;211(4):613-21 PubMed
Mol Cell Biol. 2001 Nov;21(22):7862-71 PubMed
Cell Rep. 2015 Oct 13;13(2):267-76 PubMed
Cancer Res. 2014 Feb 1;74(3):840-51 PubMed
Cell. 2010 Oct 15;143(2):225-37 PubMed
BMC Genomics. 2016 Sep 29;17(1):766 PubMed
EMBO J. 1994 Dec 1;13(23):5701-11 PubMed
Immunity. 2015 Nov 17;43(5):933-44 PubMed
EMBO J. 2011 Aug 16;30(20):4211-22 PubMed
Cell. 1991 Oct 4;67(1):11-9 PubMed
Neuropsychopharmacology. 2001 May;24(5):478-91 PubMed
Science. 2005 Sep 2;309(5740):1534-9 PubMed
Neuropsychopharmacology. 1999 Aug;21(2 Suppl):82S-90S PubMed
Neurosci Lett. 2003 Aug 7;346(3):169-72 PubMed
Leukemia. 2017 May 09;:null PubMed
Mol Cell Biol. 1995 Oct;15(10):5376-88 PubMed
Int J Oncol. 2017 Feb;50(2):622-630 PubMed
Nature. 2011 Apr 28;472(7344):481-5 PubMed
Hum Mol Genet. 2000 Sep 22;9(15):2297-304 PubMed
Mol Cell Biol. 1995 Mar;15(3):1389-97 PubMed
Sci Rep. 2017 Feb 20;7:41095 PubMed
Nat Struct Mol Biol. 2016 May;23 (5):426-33 PubMed
Cell Stem Cell. 2016 Aug 4;19(2):177-91 PubMed
Cell. 1993 Dec 31;75(7):1361-70 PubMed
J Biol Chem. 2016 Nov 25;291(48):24974-24985 PubMed
Neuron. 2017 May 17;94(4):713-730 PubMed
Cell Mol Life Sci. 2013 Jun;70(11):1875-95 PubMed
Cell Rep. 2017 Jun 20;19(12 ):2613-2626 PubMed
RNA. 2000 May;6(5):687-97 PubMed
Neuron. 2002 May 30;34(5):759-72 PubMed
J Clin Invest. 2012 Nov;122(11):4059-76 PubMed
J Neurosci. 2010 Sep 8;30(36):11917-25 PubMed
J Clin Neurosci. 2016 Oct;32:128-9 PubMed
Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11457-61 PubMed
RNA Biol. 2012 Aug;9(8):1054-65 PubMed
Genetica. 1999;106(1-2):37-47 PubMed
J Mol Biol. 2005 Aug 19;351(3):496-507 PubMed
Proc Natl Acad Sci U S A. 1962 Apr 15;48:613-6 PubMed
J Cell Sci. 2003 May 1;116(Pt 9):1805-18 PubMed
Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13532-6 PubMed
World J Biol Psychiatry. 2013 Dec;14(8):590-601 PubMed
Sci Rep. 2015 Oct 09;5:14941 PubMed
Curr Biol. 2012 Sep 11;22(17):R733-40 PubMed
Nat Rev Immunol. 2015 Jul;15(7):429-40 PubMed
Proc Natl Acad Sci U S A. 2013 Jan 15;110(3):1041-6 PubMed
J Biol Chem. 2003 Nov 14;278(46):45833-42 PubMed
Genome Res. 2009 Jun;19(6):978-86 PubMed
The effects of RNA editing in cancer tissue at different stages in carcinogenesis
Interplays of different types of epitranscriptomic mRNA modifications